Biocorp Production

Biocorp Production Equity

Delisted

The The Equity of Biocorp Production (ALCOR.PA) as of Oct 26, 2026 is 2.46 M EUR. In the previous year, The Equity was 3.12 M EUR — a change of -21.21% (lower).

Equity

2.46 MEUR

YoY

-21.21%

Last updated:

In 2022, Biocorp Production's equity was 2.46 M EUR, a -21.21% increase from the 3.12 M EUR equity in the previous year.

The Biocorp Production Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
7.06 M EUR
Jan 1, 2016
6.24 M EUR
Jan 1, 2017
-1.26 M EUR
Jan 1, 2018
-1.82 M EUR
Jan 1, 2019
31,882.00 EUR
Jan 1, 2020
2.84 M EUR
Jan 1, 2021
3.12 M EUR
Jan 1, 2022
2.46 M EUR
The Biocorp Production Equity history
YEAREquityYoY
2.46 MEUR-21.21%
3.12 MEUR+9.97%
2.84 MEUR+8,806.29%
31,882.00EUR-101.75%
-1.82 MEUR+43.97%
-1.26 MEUR-120.24%
6.24 MEUR-11.58%
7.06 MEUR+1,661.21%
401,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocorp Production Stock analysis

What does Biocorp Production do? Biocorp Production SA is a French company in the medical technology industry that manufactures innovative solutions for drug administration and injections. It was founded in 2004 under the name Biocorp sur mesure by Eric Dessertenne and later transformed into Biocorp Production SA. The business model of Biocorp Production SA is to produce innovative medical devices that can be used in medical applications. The company specializes in the development of smart devices that support injection administration. The devices produced by Biocorp can be operated by medical professionals or by patients themselves. One of the core areas of Biocorp Production SA is the development of smart medical technologies that aid in medication management. One such product is Vyoo, a device that assists patients in injecting medications. It is a digital device that facilitates injection administration and makes dosing safer. In addition to developing smart devices, Biocorp also offers other services, such as in the field of clinical trials for medical applications. The company works closely with pharmaceutical companies to develop medical devices and solutions for drug administration. Another important product is Mallya, an intelligent insulin administration system specifically designed for diabetes patients. It enables automated insulin administration tailored to the patient's needs, thereby improving their quality of life. Furthermore, Biocorp Production SA is also involved in the field of wearable medical technology. One example of a wearable device is Easylog, an electronic device for monitoring medical conditions. This device is particularly useful for patients with chronic diseases such as diabetes or asthma. Over the years, Biocorp Production SA has received numerous awards for its innovative products and services. For example, the company received the Innovation Award at the "Innovation Awards" in Paris in 2017 for the Mallya device. Overall, the company currently employs over 60 employees and has its headquarters in Issoire. It has branches in Germany and the USA. The products of Biocorp Production SA are sold in more than 80 countries worldwide. In summary, Biocorp Production SA is a leading provider of smart medical devices for drug administration and injections. The company strives to develop innovative solutions for the medical industry that are tailored to the needs of patients and medical professionals. With the products of Biocorp Production SA, medication administration becomes safer, easier, and more accurate. Biocorp Production is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Biocorp Production's Equity

Biocorp Production's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Biocorp Production's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Biocorp Production's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Biocorp Production's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Biocorp Production’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Biocorp Production stock

The Equity of Biocorp Production is 2.46 M EUR in 2022.

The Equity of Biocorp Production changed from 3.12 M EUR to 2.46 M EUR, representing a -21.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Biocorp Production since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Biocorp Production historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biocorp Production

All Key Metrics — Biocorp Production